Kidney Cancer Market, by Therapeutic Class (Immunotherapy, Targeted Therapy), by Pharmacologic Class (Angiogenesis Inhibitors, Cytokine Immunotherapy, mTOR Inhibitors, Monoclonal Antibodies), and By Geography (NA, EU, APAC, LATAM and MEA) – Analysis, Share, Trends, Size, & Forecast From 2020 – 2026

Report ID: AMI-95945444 | Publihed: 01-Jul-2020 | No of Pages: 180


USD 3995
USD 5795


Publish Date:


Total pages:


Kidney cancer market was valued at USD 5.31 billion by 2019, growing with 5.1% CAGR during the forecast period, 2020-2026
Market Dynamics
Kidney cancer is among the most common cancer observed these days, which falls within the top ten most common cancer in both female and male. As per a study by the American Cancer Society (ACS), nearly 64,000 adults are diagnosed with kidney cancer every year in the U.S. of which about 64% are male. In addition, the average age of diagnosis is 64 years and above. Thus, growing prevalence of kidney cancer owing to adoption of unhealthy lifestyles such as less physical activity, drinking, and smoking and approval of novel drugs for treatment are the major factors driving the growth of global kidney cancer drugs market.
In addition, immunotherapies would arise as an opportunity for innovators in the market. Furthermore, a huge number of the undiagnosed patient base in the untapped geographies will likely create lucrative opportunities for the market vendors. However, increasing preference for generic drugs and high costs associated with branded drugs to treat cancer are expected to hamper the market growth in the coming future.
Segment Takeaway
Targeted therapy will be high in demand owing to the rising preference of immune-oncologic agents and novel immunotherapies. Several forms of cancer treatment methods have been instigated amongst the currently approved drugs such as cytokine therapy, immune modulation therapy, mTOR inhibitor, and VEGF inhibitor. Thus, the targeted therapy segment is estimated to hold the largest market share in the projected timeframe. In addition, it is also predicted that the combination regiments of PD-1 inhibitors will be introduced in the first place to target major unmet needs such as maintaining the quality of life, enhancing progression-free survival, and overcoming tumour resistance.
The drug development for kidney cancer focuses on using novel treatments as kidney cancer is not responsive to traditional treatments of cancer treatments. PD-L1 and PD-1 inhibitors represent a model shift in the treatment of kidney cancer. Several PD-L1 and PD-1 agents with fresh MoAs are in early stages of development and are being estimated both as monotherapy and with immune-oncology agents that are already approved. Thus, it is estimated that mTOR inhibitors will be the fastest-growing segment during the forecast period.
Regional Takeaway
Presently, the North America region is estimated to subjugate the global kidney cancer drugs market trailed by Europe and the Asia Pacific. Presence of large patient pool & major market vendors and well-established healthcare infrastructure is driving the growth of North America kidney cancer drugs market. On the other hand, growing prevalence of kidney cancer and increasing government initiatives to enhance healthcare facilities in the developing economies of Asia Pacific will help the region to grow at the fastest rate during the forecast period.
In kidney cancer therapeutics, biosimilar development is gaining popularity as a promising market opportunity. The prominent players of the industry are adopting several strategies such as commercial expansion, clinical collaborations, and novel product development to increase their market share. These players functioning in the global market include:
• Bayer Healthcare
• Novartis AG
• Prometheus Labs
• Eisai Co., Ltd.
• Bristol-Myers Squibb
• Genentech (Roche)
• Exelixis
• Pfizer, Inc.
The market size and forecast for each segment and sub-segments has been considered as below:
• Historical Year – 2015 to 2018
• Base Year – 2019
• Estimated Year – 2020
• Projected Year – 2026
? Traders, Distributors, and Suppliers
? Manufacturers
? Government and Regional Agencies
? Research Organizations
? Consultants
? Distributors
The scope of this report covers the market by its major segments, which include as follows:
? Targeted Therapy
? Immunotherapy
? Others
? Cytokine Immunotherapy (IL-2)
? Angiogenesis Inhibitors
? Mammalian Target of Rapamycin (mTOR) Inhibitors
? Monoclonal Antibodies
? Others
? North America
o The U.S.
o Canada
? Europe
o Germany
o France
o Italy
o Spain
o United Kingdom
o Rest of Europe
? Asia Pacific
o India
o China
o South Korea
o Japan
o Singapore
o Rest of APAC
? Latin America
o Brazil
o Mexico
o Argentina
o Rest of LATAM
? Middle East and Africa
o Saudi Arabia
o United Arab Emirates
o Rest of MEA

Report Subsumes the following

Competitors Analysis Go To Market Strategies
Regional Coverage with precise Market Numbers Global Impact post Covid-19
Market Penetration Strategies Granular breakdown By Type and By Application.